C3N-04180
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 71.04175222
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.460
- MYC_TARGETS_V1+0.460
- G2M_CHECKPOINT+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- PANCREAS_BETA_CELLS+0.310
- MYC_TARGETS_V2+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.270
- SPERMATOGENESIS+0.220
- MTORC1_SIGNALING+0.190
- GLYCOLYSIS+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.650
- INTERFERON_GAMMA_RESPONSE-0.570
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.440
- COMPLEMENT-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- INFLAMMATORY_RESPONSE-0.380
- IL2_STAT5_SIGNALING-0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- APOPTOSIS-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013537 | — | cohortA3 | 0.908 |
| 2 | MBCProject_0006_T1_RNA | — | B | 0.887 |
| 3 | X7c81e3d9.c538.468a.8a2a.f34513bac230 | — | cohortA3 | 0.882 |
| 4 | SRR5088864 | — | — | 0.882 |
| 5 | 20120289.LumB | — | B | 0.880 |
| 6 | C3N-01074 | — | cohortA3 | 0.878 |
| 7 | R354 | — | — | 0.875 |
| 8 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.874 |
| 9 | BS_JTMXAMB7 | medulloblastoma | — | 0.867 |
| 10 | BSR_04_0040_A3_S71 | — | B | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.290 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.120 | Idelalisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |